Evidence map›Paper›PMID 23111824›Full record

SynthesisJAMA2012

Age and association of kidney measures with mortality and end-stage renal disease.

Stein I Hallan, Kunihiro Matsushita, Yingying Sang, Bakhtawar K Mahmoodi, Corri Black, Areef Ishani, Nanne Kleefstra, David Naimark, Paul Roderick, Marcello Tonelli and 7 more

Abstract readMeta-Analysis
In one paragraph

Synthesis in JAMA, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 309 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
309citing papers in PubMed, 7 pooled it
32.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

309 citing papers in PubMed, 7 syntheses or guidelines pooled it, 626 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Impact of a Primary Care CKD Registry in a US Public Safety-Net Health Care Delivery System: A Pragmatic Randomized Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018
    Trial
  15. Article
  16. Blood pressure and cardiovascular risk in adults with non-proteinuric chronic kidney disease without diabetes.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

249 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 6 countries.

Stein I HallanDivision of Nephrology, Department of Medicine, St Olav University Hospital, and Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Kunihiro Matsushita
Yingying Sang
Bakhtawar K Mahmoodi
Corri Black
Areef Ishani
Nanne Kleefstra
David Naimark
Paul Roderick
Marcello Tonelli
Jack F M Wetzels
Brad C Astor
Ron T Gansevoort
Adeera Levin
Chi-Pang Wen
Josef Coresh
Chronic Kidney Disease Prognosis Consortium
Johns Hopkins University · USUniversity of Groningen · NLInstitute of Health Services and Policy Research · CANational Health Research Institutes · TWNorwegian University of Science and Technology · NORadboud University Nijmegen · NLUnited States Department of Veterans Affairs · USUniversity of Aberdeen · GBUniversity of Alberta · CAUniversity of British Columbia · CAUniversity of Southampton · GBUniversity of Wisconsin–Madison · US

Funding

VCID and Stroke in a Bi-racial National CohortU01NS041588 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUSHMAN, MARY, HOWARD, GEORGE · 2002 to 2022
$96.0M
Clinical and Translational Science Collaborative of ClevelandUL1TR000439 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI KONSTAN, MICHAEL W. · 2012 to 2016
$50.0M
THE EPIDEMIOLOGY OF AGE-RELATED OCULAR DISEASEU10EY006594 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI KLEIN, RONALD · 1987 to 2018
$17.3M
Exceptional Survival: Trajectories to Functional Aging (CHS All Stars)R01AG023629 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEWMAN, ANNE B. · 2004 to 2016
$9.5M
CHS Events Follow-up StudyR01HL080295 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M · 2009 to 2014
$6.3M
Predictors of Alheimers Disease in Mild Cognitive ImpairmentR01AG020098 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LOPEZ, OSCAR L. · 2002 to 2011
$3.7M
MORTALITY FOLLOW-UP AND ANALYSES OF MEN IN THE MRFITR01HL068140 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI NEATON, JAMES DENNIS · 2001 to 2005
$2.6M
GENDER DIFFERENCES IN OSTEOPOROSISR01AG007181 · NIA · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI BARRETT-CONNOR, ELIZABETH L · 1999 to 2002
$1.6M
CVD Predictors of Cognitive Function Trajectory over 20 YearsR01AG028507 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BARRETT-CONNOR, ELIZABETH L · 2007 to 2010
$1.2M
Hormonal trajectories in agingR01AG027058 · NIA · UNIVERSITY OF PENNSYLVANIA · PI CAPPOLA, ANNE R · 2006 to 2009
$1.2M
Novel Risk Factors for Chronic Kidney DiseaseR01DK073217 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI KLEIN, RONALD · 2006 to 2008
$800k
Novel Cardiac Risk Factors &Endothelial Function in CKDK23DK067303 · NIDDK · TUFTS MEDICAL CENTER · PI MENON, VANDANA · 2004 to 2008
$781k
Chief Scientist Office CZH/4/656NCATS NIH HHS UL1 TR000439NEI NIH HHS U10 EY006594NHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100008CNHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100010CNHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100012CNHLBI NIH HHS HHSN268201200036CNHLBI NIH HHS N01 HC015103NHLBI NIH HHS N01 HC025195NHLBI NIH HHS N01 HC035129NHLBI NIH HHS N01 HC045133NHLBI NIH HHS N01 HC055222NHLBI NIH HHS N01 HC075150NHLBI NIH HHS N01 HC085079NHLBI NIH HHS N01 HC085086NHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095169NHLBI NIH HHS R01 HL043232NHLBI NIH HHS R01 HL068140NHLBI NIH HHS R01 HL080295NIA NIH HHS R01 AG007181NIA NIH HHS R01 AG015928NIA NIH HHS R01 AG020098NIA NIH HHS R01 AG023629NIA NIH HHS R01 AG027058NIA NIH HHS R01 AG028507NIDDK NIH HHS K23 DK002904NIDDK NIH HHS K23 DK067303NIDDK NIH HHS R01 DK031801NIDDK NIH HHS R01 DK073217NIDDK NIH HHS U01 DK035073NINDS NIH HHS U01 NS041588
6 · The paper itself

Abstract

contextChronic kidney disease (CKD) is prevalent in older individuals, but the risk implications of low estimated glomerular filtration rate (eGFR) and high albuminuria across the full age range are controversial.

objectiveTo evaluate possible effect modification (interaction) by age of the association of eGFR and albuminuria with clinical risk, examining both relative and absolute risks. DESIGN, SETTING, AND

participantsIndividual-level meta-analysis including 2,051,244 participants from 33 general population or high-risk (of vascular disease) cohorts and 13 CKD cohorts from Asia, Australasia, Europe, and North/South America, conducted in 1972-2011 with a mean follow-up time of 5.8 years (range, 0-31 years).

main outcome measuresHazard ratios (HRs) of mortality and end-stage renal disease (ESRD) according to eGFR and albuminuria were meta-analyzed across age categories after adjusting for sex, race, cardiovascular disease, diabetes, systolic blood pressure, cholesterol, body mass index, and smoking. Absolute risks were estimated using HRs and average incidence rates.

resultsMortality (112,325 deaths) and ESRD (8411 events) risks were higher at lower eGFR and higher albuminuria in every age category. In general and high-risk cohorts, relative mortality risk for reduced eGFR decreased with increasing age; eg, adjusted HRs at an eGFR of 45 mL/min/1.73 m2 vs 80 mL/min/1.73 m2 were 3.50 (95% CI, 2.55-4.81), 2.21 (95% CI, 2.02-2.41), 1.59 (95% CI, 1.42-1.77), and 1.35 (95% CI, 1.23-1.48) in age categories 18-54, 55-64, 65-74, and ≥75 years, respectively (P <.05 for age interaction). Absolute risk differences for the same comparisons were higher at older age (9.0 [95% CI, 6.0-12.8], 12.2 [95% CI, 10.3-14.3], 13.3 [95% CI, 9.0-18.6], and 27.2 [95% CI, 13.5-45.5] excess deaths per 1000 person-years, respectively). For increased albuminuria, reduction of relative risk with increasing age was less evident, while differences in absolute risk were higher in older age categories (7.5 [95% CI, 4.3-11.9], 12.2 [95% CI, 7.9-17.6], 22.7 [95% CI, 15.3-31.6], and 34.3 [95% CI, 19.5-52.4] excess deaths per 1000 person-years, respectively by age category, at an albumin-creatinine ratio of 300 mg/g vs 10 mg/g). In CKD cohorts, adjusted relative hazards of mortality did not decrease with age. In all cohorts, ESRD relative risks and absolute risk differences at lower eGFR or higher albuminuria were comparable across age categories.

conclusionsBoth low eGFR and high albuminuria were independently associated with mortality and ESRD regardless of age across a wide range of populations. Mortality showed lower relative risk but higher absolute risk differences at older age.

Indexed as

AlbuminuriaGlomerular Filtration RateAdolescentAdultAgedAge FactorsCohort StudiesFemaleHumansKidneyKidney Failure, ChronicMaleMiddle AgedRiskYoung Adult

Identifiers

PMID23111824
PMCPMC3936348
OpenAlexW2096592656

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.